CHMP issues further advice on thrombosis and thrombocytopenia with Vaxzevria (AstraZeneca’s COVID-19 vaccine)

Healthcare professionals are advised that Vaxzevria must not be administered to patients with thrombosis with thrombocytopenia syndrome after receiving the vaccine and patients should be monitored for thrombosis and thrombocytopenia within 3 weeks of vaccination.

Source:

European Medicines Agency